Company Description
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease.
It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.
The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.
Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Craig Tooman |
Contact Details
Address: 72 Hammersmith Road London, W14 8TH United Kingdom | |
| Phone | 44 20 3457 6900 |
| Website | silence-therapeutics.com |
Stock Details
| Ticker Symbol | SLN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479615 |
| CUSIP Number | 82686Q101 |
| ISIN Number | US82686Q1013 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Craig A. Tooman M.B.A. | President, Chief Executive Officer and Executive Director |
| Rhonda L. Hellums | Executive Vice President, Chief Financial Officer and Secretary |
| Dr. Steven J. Romano M.D. | Executive Vice President and Chief Research and Development Officer |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer |
| Gem Gokmen Hopkins | Head of IR and Corporate Communications |
| Gianine Esposito | Chief Human Resources Officer |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Senior Vice President and Chief Intellectual Property and Innovation Officer |
| Dr. Eric Floyd M.B.A., M.S., Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
| J.P. Gabriel | Chief Technical Operations Officer |
| Curtis Rambaran M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | SCHEDULE 13D/A | Filing |
| Mar 31, 2025 | SCHEDULE 13D/A | Filing |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 11, 2025 | SCHEDULE 13G/A | Filing |
| Jan 2, 2025 | 8-K | Current Report |
| Dec 20, 2024 | SCHEDULE 13D/A | Filing |
| Dec 9, 2024 | 6-K | Report of foreign issuer |